Next Article in Journal
Discovery, Genomic Sequence Characterization and Phylogenetic Analysis of Novel RNA Viruses in the Turfgrass Pathogenic Colletotrichum spp. in Japan
Next Article in Special Issue
HBcrAg Predicts Hepatocellular Carcinoma Development in Chronic B Hepatitis Related Liver Cirrhosis Patients Undergoing Long-Term Effective Anti-Viral
Previous Article in Journal
Recent Information on Pan-Genotypic Direct-Acting Antiviral Agents for HCV in Chronic Kidney Disease
Previous Article in Special Issue
Higher Risk of Tumor Recurrence in NASH-Related Hepatocellular Carcinoma Following Curative Resection
 
 
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Article

Comparisons of Viral Etiology and Outcomes of Hepatocellular Carcinoma Undergoing Liver Resection between Taiwan and Vietnam

1
Liver Tumor Department, Cho Ray Hospital, Ho Chi Minh City 70250, Vietnam
2
Liver Transplant Center, Department of Surgery, Kaohsiung Chang Gung Memorial Hospital and Chang Gung University College of Medicine, Kaohsiung 83300, Taiwan
3
Division of Hematology-Oncology, Department of Internal Medicine, Kaohsiung Chang Gung Memorial Hospital and Chang Gung University College of Medicine, Kaohsiung 83300, Taiwan
4
Division of Hepatogastroenterology, Department of Internal Medicine, Kaohsiung Chang Gung Memorial Hospital and Chang Gung University College of Medicine, Kaohsiung 83300, Taiwan
*
Author to whom correspondence should be addressed.
Viruses 2022, 14(11), 2571; https://doi.org/10.3390/v14112571
Submission received: 25 October 2022 / Revised: 17 November 2022 / Accepted: 19 November 2022 / Published: 20 November 2022
(This article belongs to the Special Issue Hepatitis-Associated Liver Cancer)

Abstract

:
Epidemiologic data have suggested that etiologic variations of hepatocellular carcinoma (HCC) exist in different geographic areas, and might be associated with different outcomes. We compared the viral etiology, clinicopathological characteristics and surgical outcomes between 706 Taiwanese and 1704 Vietnamese patients with HCC undergoing liver resection. Vietnamese patients had a significantly higher ratio of hepatitis B virus (HBV) (p < 0.001) and a lower ratio of hepatitis C virus (HCV) (p < 0.001) and non-B non-C than Taiwanese patients. Among patients with HBV or non-B non-C, the mean age was younger in Vietnam than in Taiwan (p < 0.001, p = 0.001, respectively). The HCC patients in Vietnam had significantly higher serum alpha-fetoprotein (AFP) levels (p < 0.001), larger tumors (p < 0.001), and a higher ratio of macrovascular invasion (p < 0.001) and extrahepatic metastasis (p < 0.001), compared to those in Taiwan. Patients treated in Vietnam had a higher tumor recurrent rate (p < 0.001), but no difference in overall survival was found between both groups. In subgroup analysis, the recurrent rate of HCC was the highest in patients with dual HBV/HCV, followed by HCV or HBV, and non-B non-C (p < 0.001). In conclusion, although the viral etiology and clinicopathological characteristics of HCC differed, postoperative overall survival was comparable between patients in Taiwan and Vietnam.

1. Introduction

Hepatocellular carcinoma (HCC) is the sixth most commonly occurring malignancy, and one of the largest contributors of cancer-related death in the world [1]. Despite recent advances in surgical technique and diagnostic modality, the overall five-year survival rate of HCC is still unsatisfactory [2]. In some developing countries of Asia and Africa, the annual incidence and mortality of HCC have been increasing [3]. Currently, chronic infection with hepatitis B virus (HBV) or hepatitis C virus (HCV) remains the most important risk factors for HCC [4]. Nevertheless, some other factors, include alcohol consumption, metabolic diseases, such as diabetes mellitus and obesity, and environmental toxins, such as alfatoxin, have become increasingly important etiologic factors [5,6,7].
Several epidemiologic studies have suggested that HCC in different geographic areas of the world may represent different forms of the disease [3]. It is worth investigating whether the regional differences in HCC characteristics and outcomes are due to different etiologies and underlying liver damage. HCC is highly prevalent in the Asia–Pacific region, where HBV infection plays the predominant role in the development of HCC [8]. In Vietnam, HCC is a serious public health issue, with age-adjusted incidence rates of over 20 per 100,000 people [3,9]. Moreover, the estimated incidence of HBV-related HCC is predicted to continue rising from 9400 in 1990 to 25,000 in 2025, even though universal infant HBV vaccination has been conducted [10,11]. In Taiwan, HCC is a leading cause of cancer-related mortality, and HBV infection is the most important viral etiology. As time moves on, the proportion of HCV-related HCC has been gradually increasing [12,13].
We, therefore, conducted a retrospective cohort study to compare the viral etiologies, clinicopathological characteristics and surgical outcomes, including overall survival (OS) and recurrence-free survival (RFS), after resection in patients with HCC treated at two tertiary centers in Taiwan and Vietnam.

2. Materials and Methods

Between January 2014 and December 2018, a total of 706 patients in Taiwan and 1704 patients in Vietnam who underwent attempted curative resection for HCC as initial treatment were enrolled. Kaohsiung Chang Gung Memorial Hospital is currently the largest one in southern Taiwan, at which the patients come from all areas of southern Taiwan [12]. Cho Ray hospital is the largest tertiary referral hospital in southern and central Vietnam, with 24,000 cases of HCC seen over a seven-year period [14]. Clinical and pathological data from all patients, including age, gender, viral hepatitis markers, preoperative serum alpha-fetoprotein (AFP) level, tumor size, tumor number, macrovascular invasion and extrahepatic metastasis were collected. This study was approved by the institutional review board of the hospital, and was conducted in accordance with the principles of the Declaration of Helsinki and the International Conference on Harmonization for Good Clinical Practice.
Data are presented as mean ± standard deviation (SD). Comparisons of differences in categorical data between groups were performed using the chi-square test. Distributions of continuous variables were analyzed by the t-test or one-way ANOVA test with least significant difference (LSD) post-hoc correction between groups where appropriate. The starting date of follow-up of each patient began at the time of liver resection. OS or RFS were measured until death from any cause or the last follow-up. Survival curves were constructed using Kaplan–Meier curves and the differences between groups were compared using the log-rank test. Furthermore, Cox proportional hazards models were used to compute the hazard ratios (HRs) with 95% confidence interval (CI), after adjustment for potential confounders. All of these analyses were carried out using statistical software (SPSS 15.0), and statistical significance was defined as a two-tailed p value of <0.05.

3. Results

3.1. Baseline Characteristics

The comparison of baseline characteristics of patients and tumors between Taiwan and Vietnam are shown in Table 1. There was a male predominance in both groups; whereas patients in Vietnam had a higher male to female ratio than those in Taiwan (p < 0.001). The HCC patients in Vietnam were younger (p < 0.001), and had significantly higher serum AFP level (p < 0.001), larger size of tumor (p < 0.001) and tended to have a single tumor (p < 0.001), having macrovascular invasion (p < 0.001) and extrahepatic metastasis (p < 0.001), compared to those in Taiwan. The most common viral etiology was HBV in both groups, but Vietnamese patients had a significantly higher ratio of HBV (p < 0.001) and a lower ratio of HCV (p < 0.001) and non-B non-C than Taiwanese patients.

3.2. Differences in Age and Gender According to Viral Etiology of HCC

Table 2 shows the differences in age and gender according to viral etiology of HCC between Taiwan and Vietnam. The mean age of HBV patients was significantly younger than that of patients with HCV (both p < 0.001) or non-B non-C (both p < 0.001) in both groups. Among patients with HBV or non-B non-C, the mean age was younger in Vietnam than in Taiwan (p < 0.001, p = 0.001, respectively), whereas there was no difference among those with HCV. The male-to-female ratio was higher in HBV than in HCV patients (p < 0.001) only in the Taiwanese group.

3.3. Factors Associated with RFS

As shown in Figure 1A, 332 patients in Taiwan and 1049 patients in Vietnam had tumor recurrence during the follow-up period (p < 0.001). In Table 3, multivariate Cox proportional hazards analysis showed the significant risk factors of tumor recurrence for HCC patients receiving hepatic resection were the following: site (HR: 2.06, 95% CI: 1.79–2.37; p < 0.001), male gender (HR: 1.37, 95% CI: 1.17–1.59; p < 0.001), higher AFP (≥400 ng/mL) (HR: 1.44, 95% CI: 1.29–1.61; p < 0.001), larger tumor size (≥5 cm) (HR: 1.37, 95% CI: 1.21–1.55; p < 0.001), multiple tumors (HR: 1.45, 95% CI: 1.27–1.67; p < 0.001), macrovascular invasion (HR: 2.17, 95% CI: 1.83–2.57; p < 0.001) and extrahepatic metastasis (HR: 2.20, 95% CI: 1.67–2.90; p < 0.001).
In regard to the viral etiology contributing to tumor recurrence, we, therefore, analyzed the patients who were classified into four groups accordingly. As shown in Figure 2, the incidence of HCC recurrence was the highest in patients with dual HBV/HCV infection, followed by HCV or HBV mono-infection, and non-B non-C (p < 0.001).

3.4. Factors Associated with OS

The OS between Taiwan and Vietnam was not different, as shown in Figure 1B. In Table 4, the significant factors associated with OS in HCC patients receiving hepatic resection were the following male gender (HR: 1.39, 95% CI: 1.08–1.81; p = 0.012), higher AFP (≥400 ng/mL) (HR: 1.60, 95% CI: 1.32–1.93; p < 0.001), larger tumor size (≥5 cm) (HR: 1.40, 95% CI: 1.14–1.72; p < 0.001), multiple tumors (HR: 1.79, 95% CI: 1.45–2.17; p < 0.001), macrovascular invasion (HR: 2.81, 95% CI: 2.18–3.62; p < 0.001) and extrahepatic metastasis (HR: 2.70, 95% CI: 1.82–4.01; p < 0.001), based on multivariate Cox proportional hazards analysis. The viral etiology was not associated with OS.

4. Discussion

This present study compared the viral etiology, clinicopathological characteristics and surgical outcomes of HCC patients receiving liver resection between Taiwan and Vietnam in the Asia–Pacific region, where the prevalence of HCC is the highest worldwide. We demonstrated that HCC patients in Vietnam were younger, and had more aggressive tumor characteristics, such as higher serum AFP level, larger size of tumor, more macrovascular invasion and more extrahepatic metastasis, compared to those in Taiwan. The patients treated in Vietnam had a significant tumor recurrent rate after resection by multivariate analysis, in addition to other common risk factors, including male gender, higher AFP, larger tumor size, multiple tumors, macrovascular invasion and extrahepatic metastasis. However, despite these differences, the postoperative OS was compatible between Taiwan and Vietnam. Although the definite reason was unclear, this might be explained by the shorter mean follow-up period in Vietnam than in Taiwan.
Globally, the male-to-female ratio of HCC patients has been reported to range from 2:1 to 5:1, with the variations associated with dominant hepatitis virus in the population and the existence of other risk factors [15]. In this study, the male-to-female ratio was higher in HBV than in HCV patients in the Taiwanese group, but not in the Vietnamese group. This finding could be partially explained by the fact that Vietnamese patients had a lower ratio of HCV infection than those in Taiwan. On the other hand, we found that HBV patients was significantly younger than patients with HCV or non-B non-C among both Taiwanese and Vietnamese patients. These data were compatible with those reported in previous studies [12,13], suggesting that age distribution of HCC depended on gender, etiology and region. However, in particular, the mean age was younger in Vietnam than in Taiwan among patients with HBV or non-B non-C, indicating that some risk factors, other than the hepatitis virus, such as agricultural use of organophosphorous pesticides or alfatoxin, should be considered in Vietnam [16,17].
Several clinicopathological factors have been constantly reported to have prognostic value following liver resection of HCC [12,18,19]. In this study, we demonstrated that male gender, higher AFP (≥400 ng/mL), larger tumor size (≥5 cm), multiple tumors, macrovascular invasion and extrahepatic metastasis were independent factors associated with poorer OS. Our data were consistent with those reported in most studies. In contrast, there was no significant difference in OS between Taiwan and Vietnam.
Whether different viral etiologies have an impact on long-term outcomes in patients undergoing liver resection for HCC is unclear. Cescon et al. reported that RFS was significantly higher in non-B non-C patients compared with those with HBV [20]. A recent study demonstrated that non-B non-C HCC occurs mostly in elderly patients, and OS rate is significantly higher than that of HBV–HCC patients [21]. In regard to dual HBV/HCV infection, previous meta-analyses have confirmed that patients with dual HBV/HCV infection have an increased risk of HCC, whereas data about dual HBV/HCV infection in association with surgical outcomes in HCC patients remain limited. Our data showed that the recurrent rate of HCC after liver resection was the highest in patients with dual HBV/HCV infection, followed by HCV or HBV mono-infection, and NBNC. This result was consistent with a recent report showing that the RFS rates in patients with HBV/HCV–HCC were significantly poorer than those with HBV–HCC in a propensity score matching cohort [22]. The reason why different etiologies impact on the HCC recurrence after liver resection remains unclear. A recent report indicated the key role of regulatory T cells in the HCC immune microenvironment and their presence has been correlated with tumor progression, and invasiveness, as well as metastasis [23]. However, our study did not confirm the association of viral etiology with OS. This issue should be further clarified due to limited cases of dual HBV/HCV infection in our study.
The strength of this study was our large sample size of patients who were enrolled from two large tertiary referral centers. However, our study has the common limitations associated with its retrospective study design with some incomplete patient records and potential selection bias. In addition, our study did not analyze the treatment effect of antivirals such as nucleos(t)ide analogs for HBV, and interferon-based therapies or direct acting antivirals for HCV. Moreover, our data, such as the data on two-year recurrence and three-year survival, were compatible with those previously reported in a meta-analysis of single HCV-untreated studies, evaluating outcomes after curative treatments of HCV-related HCC [24,25]. Our study also did not analyze the effect of other treatment procedures for recurrent lesions on OS. Further studies are necessary to clarify these weak points.

5. Conclusions

This study identified the differences in viral etiology and clinicopathological characteristics, as well as surgical outcomes, between Taiwan and Vietnam. Although HCC patients in Vietnam had more aggressive tumor characteristics and higher tumor recurrence rates after resection, there was no significance in postoperative OS between Taiwan and Vietnam.

Author Contributions

Conceptualization, C.-H.H.; formal analysis, C.-H.H.; acquisition of data: S.-H.N.-D., W.-F.L., Y.-W.L., C.-C.W., Y.-H.C. and J.-H.W.; writing—original draft preparation, C.-H.H.; writing—review and editing, S.-H.N.-D. and C.-H.H. All authors have read and agreed to the published version of the manuscript.

Funding

This research received no external funding.

Institutional Review Board Statement

The study was conducted in accordance with the Declaration of Helsinki, and approved by the Institutional Review Board of Chang Gung Medical Foundation on 24 Oct 2022 (IRB No.: 202201655B0).

Informed Consent Statement

Informed consent was obtained from all subjects involved in the study.

Data Availability Statement

The data presented in this study are available on reasonable request to the first author and corresponding author.

Conflicts of Interest

The authors declare no conflict of interest.

References

  1. Llovet, J.M.; Kelley, R.K.; Villanueva, A.; Singal, A.G.; Pikarsky, E.; Roayaie, S.; Lencioni, R.; Koike, K.; Zucman-Rossi, J.; Finn, R.S. Hepatocellular carcinoma. Nat. Rev. Dis. Prim. 2021, 7, 6. [Google Scholar] [CrossRef] [PubMed]
  2. European Association for the Study of the Liver. Electronic address: [email protected]; European Association for the Study of the Liver. EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma. J. Hepatol. 2018, 69, 182–236. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  3. McGlynn, K.A.; Petrick, J.L.; El-Serag, H.B. Epidemiology of Hepatocellular Carcinoma. Hepatology 2021, 73, 4–13. [Google Scholar] [CrossRef] [PubMed]
  4. Russo, F.P.; Zanetto, A.; Pinto, E.; Battistella, S.; Penzo, B.; Burra, P.; Farinati, F. Hepatocellular Carcinoma in Chronic Viral Hepatitis: Where Do We Stand? Int. J. Mol. Sci. 2022, 23, 500. [Google Scholar] [CrossRef]
  5. Zanetto, A.; Shalaby, S.; Gambato, M.; Germani, G.; Senzolo, M.; Bizzaro, D.; Russo, F.P.; Burra, P. New Indications for Liver. Transplantation. J. Clin. Med. 2021, 10, 3867. [Google Scholar] [CrossRef]
  6. Anstee, Q.M.; Reeves, H.L.; Kotsiliti, E.; Govaere, O.; Heikenwalder, M. From NASH to HCC: Current concepts and future challenges. Nat. Rev. Gastroenterol. Hepatol. 2019, 16, 411–428. [Google Scholar] [CrossRef]
  7. Yang, J.D.; Hainaut, P.; Gores, G.J.; Amadou, A.; Plymoth, A.; Roberts, L.R. A global view of hepatocellular carcinoma: Trends, risk, prevention and management. Nat. Rev. Gastroenterol. Hepatol. 2019, 16, 589–604. [Google Scholar] [CrossRef]
  8. Zhu, R.X.; Seto, W.K.; Lai, C.L.; Yuen, M.F. Epidemiology of Hepatocellular Carcinoma in the Asia-Pacific Region. Gut Liver 2016, 10, 332–339. [Google Scholar] [CrossRef] [Green Version]
  9. Sereno, L.; Mesquita, F.; Kato, M.; Jacka, D.; Nguyen, T.T.; Nguyen, T.N. Epidemiology, responses, and way forward: The silent epidemic of viral hepatitis and HIV coinfection in Vietnam. J. Int. Assoc. Physicians AIDS Care 2012, 11, 311–320. [Google Scholar] [CrossRef]
  10. Nguyen, V.T.; Law, M.G.; Dore, G.J. An enormous hepatitis B virus related liver disease burden projected in Vietnam by 2025. Liver Int. 2008, 28, 525–531. [Google Scholar] [CrossRef]
  11. Omata, M.; Cheng, A.L.; Kokudo, N.; Kudo, M.; Lee, J.M.; Jia, J.; Tateishi, R.; Han, K.H.; Chawla, Y.K.; Shiina, S.; et al. Asia-Pacific clinical practice guidelines on the management of hepatocellular carcinoma: A 2017 update. Hepatol. Int. 2017, 11, 317–370. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  12. Changchien, C.S.; Chen, C.L.; Yen, Y.H.; Wang, J.H.; Hu, T.H.; Lee, C.M.; Wang, C.C.; Cheng, Y.F.; Huang, Y.J.; Lin, C.Y.; et al. Analysis of 6381 hepatocellular carcinoma patients in southern Taiwan: Prognostic features, treatment outcome, and survival. J. Gastroenterol. 2008, 43, 159–170. [Google Scholar] [CrossRef] [PubMed]
  13. Lu, S.N.; Su, W.W.; Yang, S.S.; Chang, T.T.; Cheng, K.S.; Wu, J.C.; Lin, H.H.; Wu, S.S.; Lee, C.M.; Changchien, C.S.; et al. Secular trends and geographic variations of hepatitis B virus and hepatitis C virus-associated hepatocellular carcinoma in Taiwan. Int. J. Cancer 2006, 119, 1946–1952. [Google Scholar] [CrossRef] [PubMed]
  14. Nguyen-Dinh, S.H.; Do, A.; Pham, T.N.D.; Dao, D.Y.; Nguy, T.N.; Chen, M.S., Jr. High burden of hepatocellular carcinoma and viral hepatitis in Southern and Central Vietnam: Experience of a large tertiary referral center, 2010 to 2016. World J. Hepatol. 2018, 10, 116–123. [Google Scholar]
  15. El-Serag, H.B. Hepatocellular carcinoma. N. Engl. J. Med. 2011, 365, 1118–1127. [Google Scholar] [CrossRef] [PubMed]
  16. Cordier, S.; Le, T.B.; Verger, P.; Bard, D.; Le, C.D.; Larouze, B.; Dazza, M.C.; Hoang, T.Q.; Abenhaim, L. Viral infections and chemical exposures as risk factors for hepatocellular carcinoma in Vietnam. Int. J. Cancer 1993, 55, 196–201. [Google Scholar] [CrossRef] [PubMed]
  17. Lee, H.S.; Lindahl, J.; Nguyen, V.H.; Khong, N.V.; Nghia, V.B.; Xuan, H.N.; Grace, D. An investigation into aflatoxin M1 in slaughtered fattening pigs and awareness of aflatoxins in Vietnam. BMC Vet. Res. 2017, 13, 363. [Google Scholar] [CrossRef]
  18. Li, C.; Chen, K.; Liu, X.; Liu, H.T.; Liang, X.M.; Liang, G.L.; Tang, S.T.; Huo, R.R.; Ma, L.; Xiang, B.B.; et al. Analysis of Clinicopathological Characteristics and Prognosis of Young Patients with Hepatocellular Carcinoma after Hepatectomy. J. Clin. Transl. Hepatol. 2020, 8, 285–291. [Google Scholar] [CrossRef]
  19. Shimada, S.; Kamiyama, T.; Orimo, T.; Nagatsu, A.; Asahi, Y.; Sakamoto, Y.; Kamachi, H.; Taketomi, A. Prognoses, outcomes, and clinicopathological characteristics of very elderly patients with hepatocellular carcinoma who underwent hepatectomy. World J. Surg. Oncol. 2020, 18, 122. [Google Scholar] [CrossRef]
  20. Cescon, M.; Cucchetti, A.; Grazi, G.L.; Ferrero, A.; Viganò, L.; Ercolani, G.; Ravaioli, M.; Zanello, M.; Andreone, P.; Capussotti, L.; et al. Role of hepatitis B virus infection in the prognosis after hepatectomy for hepatocellular carcinoma in patients with cirrhosis: A Western dual-center experience. Arch. Surg. 2009, 144, 906–913. [Google Scholar] [CrossRef] [Green Version]
  21. Tanase, A.M.; Dumitrascu, T.; Dima, S.; Grigorie, R.; Marchio, A.; Pineau, P.; Popescu, I. Influence of hepatitis viruses on clinicopathological profiles and long-term outcome in patients undergoing surgery for hepatocellular carcinoma. Hepatobiliary Pancreat. Dis. Int. 2014, 13, 162–172. [Google Scholar] [CrossRef]
  22. Jia, H.D.; Liang, L.; Li, C.; Wu, H.; Wang, H.; Liang, Y.J.; Zhou, Y.H.; Gu, W.M.; Fan, X.P.; Zhang, W.G.; et al. Long-Term Surgical Outcomes of Liver Resection for Hepatocellular Carcinoma in Patients With HBV and HCV Co-Infection: A Multicenter Observational Study. Front. Oncol. 2021, 11, 700228. [Google Scholar] [CrossRef] [PubMed]
  23. Granito, A.; Muratori, L.; Lalanne, C.; Quarneti, C.; Ferri, S.; Guidi, M.; Lenzi, M.; Muratori, P. Hepatocellular carcinoma in viral and autoimmune liver diseases: Role of CD4+ CD25+ Foxp3+ regulatory T cells in the immune microenvironment. World J. Gastroenterol. 2021, 27, 2994–3009. [Google Scholar] [CrossRef] [PubMed]
  24. Cabibbo, G.; Petta, S.; Barbàra, M.; Missale, G.; Virdone, R.; Caturelli, E.; Piscaglia, F.; Morisco, F.; Colecchia, A.; Farinati, F.; et al. A meta-analysis of single HCV-untreated arm of studies evaluating outcomes after curative treatments of HCV-related hepatocellular carcinoma. Liver Int. 2017, 37, 1157–1166. [Google Scholar] [CrossRef] [PubMed]
  25. Garuti, F.; Neri, A.; Avanzato, F.; Gramenzi, A.; Rampoldi, D.; Rucci, P.; Farinati, F.; Giannini, E.G.; Piscaglia, F.; Rapaccini, G.L.; et al. The changing scenario of hepatocellular carcinoma in Italy: An update. Liver Int. 2021, 41, 585–597. [Google Scholar] [CrossRef] [PubMed]
Figure 1. (A). Recurrence-free survival after resection of HCC, stratified by site of treatment. (B). Overall survival after resection of HCC, stratified by site of treatment.
Figure 1. (A). Recurrence-free survival after resection of HCC, stratified by site of treatment. (B). Overall survival after resection of HCC, stratified by site of treatment.
Viruses 14 02571 g001
Figure 2. Recurrence-free survival after resection of HCC, stratified by viral etiology.
Figure 2. Recurrence-free survival after resection of HCC, stratified by viral etiology.
Viruses 14 02571 g002
Table 1. Comparison of patient and tumor characteristics.
Table 1. Comparison of patient and tumor characteristics.
VariableTaiwanVietnamp-Value
n%n%
Total706 1704
Gender <0.001
  Male548(77.6)1433(84.1)
  Female158(22.4)271(15.9)
Age (years) <0.001
  <60289(40.9)1064(62.4)
  ≥60417(59.1)640(37.6)
  Mean (SD)60.9(11.0)54.6(12.3)
Viral hepatitis <0.001
  HBV342(48.4)1246(73.1)
  HCV197(27.9)216(12.7)
  HBV/HCV20(2.8)36(2.1)
  Non HBV/HCV147(20.8)206(12.1)
Alpha-fetoprotein (ng/mL) <0.001
  <400567(80.3)931(54.6)
  ≥400138(19.7)773(45.4)
  Mean (SD)4653(30,824)13,093(54,535)
Tumor size (cm) <0.001
  <5469(66.4)394(23.1)
  ≥5237(33.6)1310(76.9)
  Mean (SD)4.9(3.8)7.2(3.7)
Tumor number <0.001
  Single487(72.7)1457(85.5)
  Multiple183(27.3)247(14.5)
Macrovascular invasion <0.001
  No644(96.1)1532(90.0)
  Yes26(3.9)172(10.0)
Extrahepatic metastasis <0.001
  No663(99.0)1644(96.5)
  Yes7(1.0)60(3.5)
Table 2. Differences in age and gender according to viral etiology of HCC.
Table 2. Differences in age and gender according to viral etiology of HCC.
HBVHCV B + C NBNCp-Value
Taiwan
  Case no.34219720147
  Age (years) *57.5 ± 11.3 acf65.3 ± 8.3 ad59.5 ± 9.1 d63.1 ± 11.4 ch<0.001
  Gender (M/F)287/55 (5.2) a126/71 (1.8) aeg17/3 (5.7)118/29 (4.1) e<0.001
Vietnam
  Case no.124621636206
  Age (years) *52.0 ± 11.8 acf65.2 ± 7.5 ad56.8 ± 13.1 d59.0 ± 11.8 ch<0.001
  Gender (M/F)1057/189 (5.6)175/41 (4.3) g33/3 (11)168/38 (4.4)0.206
* Mean ± SD; p-value by one-way ANOVA test with least significant difference (LSD) post-hoc correction or x2 test. a Significant differences between HBV and HCV; b Significant differences HBV and B + C; c Significant differences between HBV and Non-B, Non-C; d Significant differences between HCV and B + C; e Significant differences HCV and Non-B, Non-C; f Significant differences between Taiwan and Vietnam HBV-HCC; g Significant differences between Taiwan and Vietnam HCV–HCC; h Significant differences between Taiwan and Vietnam NBNC–HCC.
Table 3. Risk of recurrence-free survival for HCC patients receiving hepatic resection.
Table 3. Risk of recurrence-free survival for HCC patients receiving hepatic resection.
VariableHR (95% CI)p-ValueaHR (95% CI) *p-Value
Site <0.001 <0.001
  TaiwanReference Reference
  Vietnam2.44 (2.15–2.77) 2.06 (1.79–2.37)
Sex 0.015 <0.001
  FemaleReference Reference
  Male1.38 (1.20–1.60) 1.37 (1.17–1.59)
Age (years) 0.003
  <60Reference
  ≥600.86 (0.77–0.95)
HBsAg <0.001
  Positive1.26 (1.12–1.41)
  NegativeReference
Anti-HCV 0.509
  Positive0.96 (0.84–1.09)
  NegativeReference
Alpha-fetoprotein (ng/mL) <0.001 <0.001
  <400Reference Reference
  ≥4001.82 (1.63–2.02) 1.44 (1.29–1.61)
Tumor size (cm) <0.001 <0.001
  <5Reference Reference
  ≥51.98 (1.76–2.22) 1.37 (1.21–1.55)
Tumor number <0.001 <0.001
  SingleReference Reference
  Multiple1.37 (1.20–1.56) 1.45 (1.27–1.67)
Macrovascular invasion <0.001 <0.001
  NoReference Reference
  Yes2.82 (2.38–3.33) 2.17 (1.83–2.57)
Extrahepatic metastasis <0.001 <0.001
  NoReference Reference
  Yes2.85 (2.17–3.75) 2.20 (1.67–2.90)
* Multivariable analysis by Cox proportional hazards model.
Table 4. Risk for HCC patients receiving hepatic resection.
Table 4. Risk for HCC patients receiving hepatic resection.
VariableHR (95% CI)p-ValueaHR (95% CI) *p-Value
Site 0.182
  TaiwanReference
  Vietnam0.88 (0.73–1.06)
Sex 0.015 0.012
  FemaleReference Reference
  Male1.37 (1.06–1.76) 1.39 (1.08–1.81)
Age (years) 0.652
  <60Reference
  ≥601.04 (0.87–1.25)
HBsAg 0.847
  Positive0.98 (0.81–1.18)
  NegativeReference
Anti-HCV 0.711
  Positive0.96 (0.77–1.20)
  NegativeReference
Alpha-fetoprotein (ng/mL) <0.001 <0.001
  <400Reference Reference
  ≥4001.87 (1.56–2.24) 1.60 (1.32–1.93)
Tumor size (cm) <0.001 0.001
  <5Reference Reference
  ≥51.72 (1.41–2.10) 1.40 (1.14–1.72)
Tumor number <0.001 <0.001
  SingleReference Reference
  Multiple2.08 (1.69–2.56) 1.79 (1.45–2.17)
Macrovascular invasion <0.001 <0.001
  NoReference Reference
  Yes3.79 (2.96–4.84) 2.81 (2.18–3.62)
Extrahepatic metastasis <0.001 <0.001
  NoReference Reference
  Yes3.62 (2.45–5.35) 2.70 (1.82–4.01)
* Multivariable analysis by Cox proportional hazards model.
Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Share and Cite

MDPI and ACS Style

Nguyen-Dinh, S.-H.; Li, W.-F.; Liu, Y.-W.; Wang, C.-C.; Chen, Y.-H.; Wang, J.-H.; Hung, C.-H. Comparisons of Viral Etiology and Outcomes of Hepatocellular Carcinoma Undergoing Liver Resection between Taiwan and Vietnam. Viruses 2022, 14, 2571. https://doi.org/10.3390/v14112571

AMA Style

Nguyen-Dinh S-H, Li W-F, Liu Y-W, Wang C-C, Chen Y-H, Wang J-H, Hung C-H. Comparisons of Viral Etiology and Outcomes of Hepatocellular Carcinoma Undergoing Liver Resection between Taiwan and Vietnam. Viruses. 2022; 14(11):2571. https://doi.org/10.3390/v14112571

Chicago/Turabian Style

Nguyen-Dinh, Song-Huy, Wei-Feng Li, Yueh-Wei Liu, Chih-Chi Wang, Yen-Hao Chen, Jing-Houng Wang, and Chao-Hung Hung. 2022. "Comparisons of Viral Etiology and Outcomes of Hepatocellular Carcinoma Undergoing Liver Resection between Taiwan and Vietnam" Viruses 14, no. 11: 2571. https://doi.org/10.3390/v14112571

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Metrics

Back to TopTop